Applies to glyburide: oral tablet
Along with its needed effects, glyburide may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking glyburide:
Incidence not known
Get emergency help immediately if any of the following symptoms of overdose occur while taking glyburide:
Symptoms of overdose
Some side effects of glyburide may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Incidence not known
Applies to glyburide: compounding powder, oral tablet
Like all sulfonylureas, this drug may commonly cause hypoglycemia and in some case it may be severe. Proper patient selection, dose, and patient instructions are important to avoid hypoglycemic episodes.
Very rare (less than 0.01%): Disulfiram-like reaction
Frequency not reported: Hypoglycemia, hyponatremia, weight gain, lactic acidosis, syndrome of inappropriate antidiuretic hormone (SIADH) secretion
Frequency not reported: Hepatic porphyria
Very common (10% or more): Hypoglycemia
Adverse gastrointestinal effects occur in about 1% to 2% of patients and appear to be dose related; they may subside following a dose reduction. Pancreatitis has been reported rarely.
Common (1% to 10%): Nausea, vomiting, epigastric fullness or sensation of pressure, abdominal pain, anorexia, dyspepsia, diarrhea, heartburn
Rare (less than 0.1%): Pancreatitis
Very common (10% or more): Transitory diarrhea, abdominal pain, vomiting, dyspepsia
Common (1% to 10%): Tooth discoloration
Very rare (less than 0.01%): Allergic vasculitis
Frequency not reported: Allergic skin reactions including pruritus, erythema, urticaria, and morbilliform or maculopapular eruptions, angioedema, arthralgia, myalgia, vasculitis, erythema multiforme, erythema nodosum, bullous eruptions, exfoliative dermatitis, photosensitivity, Stevens-Johnson syndrome
Allergic skin reactions including pruritus, erythema, urticaria, and morbilliform or maculopapular eruptions occurred in 1.5 % of patients during clinical trials. In some cases these were transient and disappeared despite continue therapy. Hypersensitivity reactions affecting the skin usually occur within the first 6 weeks of treatment with a sulfonylurea.
Common (1% to 10%): Allergic skin reactions including pruritus, erythema, urticaria, and morbilliform or maculopapular eruptions
Frequency not reported: Alopecia/hypotrichoses, increased sweating, facial edema, angioedema, bullous reactions, erythema multiforme, exfoliative dermatitis
-Frequency not reported: Porphyria cutanea tarda, photosensitivity reactions
Allergic skin reactions including pruritus, erythema, urticaria, morbilliform, erythematous and maculopapular and bullous skin eruptions or psoriasiform drug eruptions occurred in 1.5 % of patients during clinical trials. These may be transient and may disappear despite continued therapy. Bullous reactions, erythema multiforme, and exfoliative dermatitis have been reported. If skin reactions persist, this drug should be discontinued.
Changes in accommodation and/or blurred vision are thought to be related to fluctuations in glucose levels.
Frequency not reported: Changes in accommodation and/or blurred vision, diplopia, visual disturbances, blindness
Postmarketing reports: Hemolytic anemia
Frequency not reported: Leukopenia, agranulocytosis, thrombocytopenia, thrombocytopenia purpura, eosinophilia, bone marrow aplasia, coagulation disorders, hemolytic anemia, aplastic anemia, anemia, pancytopenia
Rare (less than 0.1%): Cholestatic jaundice, hepatitis
Frequency not reported: Liver function abnormalities including isolated transaminase elevations
Frequency not reported: Increased liver enzymes (AST, ALT), abnormal liver function, cholestasis, cholestatic hepatitis, granulomatous hepatitis, bilirubinemia
Very common (10% or more): Transient increased transaminases
Frequency not reported: Abnormal renal function, acute renal failure
Frequency not reported: Arthralgia, arthritis
Frequency not reported: Paresthesia, tremor, convulsions, encephalopathy, confusion, headache, cerebrovascular disorders
Frequency not reported: Deafness, fever
Frequency not reported: Acute psychosis
Medically reviewed by USARx EDITORIAL TEAM Last updated on 1/1/2020.
Source: Drugs.com Glyburide (www.drugs.com/glyburide.html).